12th Conference on Retrovirus and Opportunistic Infections, 22-25 February, Boston, 2005
As is customary for this scientific meeting, Retrovirus this year provided an opportunity for important research.
Abstracts from this meeting are posted to the conference website, and many pdf for poster presentations are also already online:
There was a wealth of exciting data on new compounds with an indication to work against currently resistant HIV, and important overviews that this year are available as online webcasts, with slides.
Particularly recommended presentations include:
February 23, 2005
Plenary: Nevirapine and PMTCT
- Controversies in the use of nevirapine for the prevention of mother-to-child transmission – James McIntyre
Symposium: Chemokine Receptor Blockade: Bench to Bedside
- Preclinical development of chemokine receptor inhibitors – Donald E Mosier
- Clinical activity and efficacy trials of chemokine receptor inhibitors – Daniel Kuritzkes
Symposium: Heart and HAART
- Cardiovascular risk prediction in the general population – Jorge Plutzky
- Cardiovascular outcomes in HIV infection – Jens D Lundgren
- Managing cardiovascular risk and lipid disorders – Esteban Martinez
February 24, 2005
- Fitting the pieces of the puzzle – Peter Reiss
Symposium: Critical Paediatric Issues in Developing Countries
- Safer breastfeeding for babies born to HIV-positive mothers: part of the answer to a dilemma – Jean Humphrey
- Is early diagnosis of HIV infection feasible in resource-limited settings? – Christine Rouzioux
- Paediatric antiretroviral therapy: challenges and triumphs – Diana Gibb
Special Symposium: Transmitted HIV-1 Drug Resistance and Rapid Disease Progression
- Introductory remarks and summary of case report of recent infection by a multi-drug resistant, dual-tropic HIV-1 in association with rapid progression to AIDS – David Ho
- Variations in the natural history of HIV infection in the NIAID Multicenter AIDS Cohort Study (MACS) and the Women’s Interagency HIV Study (WIHS) – Stephen Gange
- Variations in the natural history of HIV seroconverters in US military cohorts – Matthew Dolan
- Transmission of drug resistant HIV: frequency, transmissibility, and fitness – Andrew Leigh Brown
- Public health aspects of the NYC case – Harold Jaffe
With over 900 studies and presentations we are only able to include a few reports in this issue of HTB. Further reports will follow in the next issue.
The conference is the focus of many online web reports which are also recommended.
Amongst the most useful include:
National AIDS Treatment Advocacy Project – NATAP.
HIV and Hepatitis.com
Clinical Care Options
Reports in this issue include:
- Gut memory CD4 T cells implicated in a central role for HIV disease pathology: dramatic impact prior to seroconversion
- Case report of antibody reversion and negative viral load four-years after treatment discontinuation
- Absolute risk is modest, but cumulative cardiovascular risk of HAART over five years is similar to ‘ever smoked’: new data on gender and age
- Switch to tenofovir from AZT or d4T improves fat loss and improves lipid parameters compared to abacavir
- Continued use of a thymidine analogue may limit benefit from rosiglitazone when used to treat lipoatrophy